Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1

References

• Amundsen R, Christensen H, Zabihyan B, Asberg A. (2010). Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metabol Dispos 38:1499–504
   PubMed Web of Science ®Google Scholar
• Ayad MF, Magdy N. (2015). Application of new spectrofluorometric techniques for determination of atorvastatin and ezetimibe in combined tablet dosage form. Chem Pharm Bull 63:443–9
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim, Inc., (2014). Ofev (nintedanib) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000ClinPharmR.pdf. [last accessed 19 July 2017]
   Google Scholar
• Cagigal E, González L, Alonso RM, Jiménez RM. (2001). pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. J Pharm Biomed Anal 26:477–86
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ma L, Chang SY, et al. (2016). Application of static models to predict midazolam clinical interactions in the presence of single or multiple hepatitis C virus drugs. Drug. Drug Metab Dispos 44:1372–80
   PubMed Web of Science ®Google Scholar
• Cui Y, König J, Buchholz JK, et al. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–37
   PubMed Web of Science ®Google Scholar
• Daneshtalab N, Lewanczuk RZ, Jamali F. (2002). High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J Chromatograph B 766:345–9
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration–Center for Drug Evaluation and Research. (2012). Draft guidance: drug interaction studies–study design, data analysis, implications for dosing, and labeling recommendations. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf [last accessed 19 July 2017]
   Google Scholar
• Han JY, Lim HS, Shin ES, et al. (2008). Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59:69–75
   PubMed Web of Science ®Google Scholar
• Hu S, Mathijssen RH, de Bruijn P, et al. (2014). Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 110:894–8
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, et al. (1998). Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–412
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Komori T, et al. (2013). Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metabol Dispos 41:1859–66
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Maeda K, et al. (2015). Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos 43:235–47
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Komori T, et al. (2016). Investigation of fluorescein derivatives as substrates of organic anion transporting polypeptide (OATP) 1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays. Mol Pharm 13:438–48
   PubMed Web of Science ®Google Scholar
• Johnston RA, Rawling T, Chan T, et al. (2014). Selective inhibition of human solute carrier transporters by multikinase inhibitors. Drug Metab Dispos 42:1851–7
   PubMed Web of Science ®Google Scholar
• Katsube Y, Tsujimoto M, Koide H, et al. (2017). Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38. Cancer Chemother Pharmacol 79:783–9
   PubMed Web of Science ®Google Scholar
• Kindla J, Müller F, Mieth M, et al. (2011). Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos 39:1047–53
   PubMed Web of Science ®Google Scholar
• Khurana V, Minocha M, Pal D, Mitra AK. (2014). Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabol Drug Interact 29:249–59
   PubMedGoogle Scholar
• Lacy S, Hsu B, Miles D, et al. (2015). Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab Dispos 43:1190–207
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–75
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, et al. (2006). Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427–39
   PubMed Web of Science ®Google Scholar
• Maeda K. (2015). Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. Biol Pharm Bull 38:155–68
   PubMed Web of Science ®Google Scholar
• Marada VV, Flörl S, Kühne A, et al. (2015). Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem 92:723–31
   PubMed Web of Science ®Google Scholar
• Mross K, Steinbild S, Baas F, et al. (2007). Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43:55–63
   PubMed Web of Science ®Google Scholar
• Noé J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–14
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. (2014). Zykadia (ceritinib) Clinical pharmacology and biopharmaceutics review (S). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf. [last accessed 19 July 2017]
   Google Scholar
• Nozawa T, Minami H, Sugiura S, et al. (2005). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434–9
   PubMed Web of Science ®Google Scholar
• Ohya H, Shibayama Y, Ogura J, et al. (2015). Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull 38:582–6
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical Pharmacol Ther 82:726–33
   PubMed Web of Science ®Google Scholar
• Patik I, Kovacsics D, Német O, et al. (2015). Functional expression of the 11 human organic anion transporting polypeptides in insect cells reveals that sodium fluorescein is a general OATP substrate. Biochem Pharmacol 98:649–58
   PubMed Web of Science ®Google Scholar
• Pharmaceutical and Medical Devices Agency, Japan. (2012). The review report of votrient tablets 200 mg. Available at: https://www.pmda.go.jp/files/000153553.pdf [last accessed 19 July 2017]
   Google Scholar
• Pharmaceutical and Medical Devices Agency, Japan. (2013). The review report of giotrif tablets 20 mg, 30 mg, 40 mg, and 50 mg. Available at: https://www.pmda.go.jp/files/000210320.pdf [last accessed 19 July 2017]
   Google Scholar
• Pharmaceutical and Medical Devices Agency, Japan. (2015a). The review report of Lenvima capsules 4 mg, 10 mg. Available at: https://www.pmda.go.jp/files/000210264.pdf [Last accessed 19 July 2017]
   Google Scholar
• Pharmaceutical and Medical Devices Agency, Japan. (2015b). The review report of Ofev capsules 100 mg, 150 mg. Available from: https://www.pmda.go.jp/files/000214531.pdf [last accessed 19 July 2017]
   Google Scholar
• Prashanthi Y, Ahmed MA, Vijaya K, Riyazuddin. (2016). Method development and validation of lenvatinib drug by RP-HPLC in pharmaceutical drug dosage form. Indo Am J Pharm Sci 3:1078–85
   Web of Science ®Google Scholar
• Rao RN, Bompelli S, Maurya PK. (2011). High-performance liquid chromatographic determination of anti- hypertensive drugs on dried blood spots using a fluorescence detector-method development and validation. Biomed Chromatogr 25:1252–9
   PubMed Web of Science ®Google Scholar
• Reyes M, Benet LZ. (2011). Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci 100:3831–42
   PubMed Web of Science ®Google Scholar
• Schultheis B, Folprecht G, Kuhlmann J, et al. (2013). Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol 24:1560–7
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, et al. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–16
   PubMed Web of Science ®Google Scholar
• Talele GS, Porwal PK. (2015). Development of validated bioanalytical HPLC-UV method for simultaneous estimation of amlodipine and atorvastatin in rat plasma. Indian J Pharm Sci 77:742–50
   PubMed Web of Science ®Google Scholar
• Tamai I, Nozawa T, Koshida M, et al. (2001). Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262–9
   PubMed Web of Science ®Google Scholar
• Vaidyanathan J, Yoshida K, Arya V, Zhang L. (2016). Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1. J Clin Pharmacol 56:S59–72
   PubMed Web of Science ®Google Scholar
• Wang X, Wolkoff AW, Morris ME. (2005). Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33:1666–72
   PubMed Web of Science ®Google Scholar
• Weaver YM, Hagenbuch B. (2010). Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates. J Membrane Biol 236:279–90
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Nakagawa T, Uno T. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165–75
   PubMedGoogle Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobio-Dynam 4:879–85
   PubMedGoogle Scholar
• Yamashiro W, Maeda K, Hirouchi M, et al. (2006). Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247–54
   PubMed Web of Science ®Google Scholar